Opportunity
Our synthetic lethal target discovery approach can be adapted to identify druggable tumor-intrinsic targets that do not kill cancer cells directly, but rather attract immune cells to destroy them. In preclinical studies we have shown that Target 3, an undisclosed synthetic lethal target, reverses the immune evasion effect of STK11 (serine-threonine kinase 11) loss-of-function mutations, which are present in approximately 15% of non-squamous lung and cervical cancers, 10% of carcinoma of unknown primary, 5% of breast cancers and 3% of pancreatic cancers.